View : 500 Download: 0
Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma (R)) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+metastatic breast cancer (KCSG BR 18-14/KM10B)
- Title
- Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma (R)) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+metastatic breast cancer (KCSG BR 18-14/KM10B)
- Authors
- Sim, Sung Hoon; Kim, Jeong Eun; Kim, Min Hwan; Park, Yeon Hee; Kim, Jee Hyun; Suh, Koung Jin; Koh, Su-Jin; Park, Kyong Hwa; Kang, Myoung Joo; Ahn, Mi Sun; Lee, Kyoung Eun; Kim, Hee -Jun; Ahn, Hee Kyung; Kim, Han Jo; Park, Keon Uk; Byun, Jae Ho; Park, Jin Hyun; Lee, Gyeong-Won; Lee, Keun Seok; Sohn, Joohyuk; Jung, Kyung Hae; Park, In Hae
- Ewha Authors
- 이경은
- Issue Date
- 2022
- Journal Title
- BREAST
- Citation
- BREAST vol. 65, pp. 172 - 178
- Publisher
- CHURCHILL LIVINGSTONE
- Document Type
- Article
- Abstract
- We investigated the efficacy and safety of a trastuzumab biosimilar, Herzuma (R), in combination with treatment of physician's choice (TPC) in patients with HER2+ metastatic breast cancer (MBC) who had failed at least two HER2 directed chemotherapies.
- Appears in Collections:
- 의과대학 > 의학과 > Journal papers
- Files in This Item:
There are no files associated with this item.
- Export
- RIS (EndNote)
- XLS (Excel)
- XML
03760 서울특별시 서대문구 이화여대길 52 이화여자대학교 도서관
COPYRIGHT 2016 BY EWHA WOMANS UNIVERSITY. ALL RIGHTS RESERVED
이화여자대학교 리포지터리는 국립중앙도서관 OAK 보급사업으로 구축되었습니다. Feedback